VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | Targeting the PI3K pathway in patients who fail JAK inhibitor therapy

Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the promise of targeting the PI3K pathway in patients who fail JAK inhibitor therapy, and the potential long-term benefits of this therapeutic strategy. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Consulting/Advisory for CTI Biopharma, GSK/Sierra Oncology, Morphosys, ParmaEssentia, Imago, AbbVie

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter